{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:46:37Z","timestamp":1787996797550,"version":"build-2784847793"},"reference-count":23,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Complete molecular response (CMR) after first-line immunochemotherapy reflects treatment efficacy and may predict prognosis in patients with follicular lymphoma (FL). RELEVANCE is the first phase 3 trial comparing the chemotherapy-free regimen lenalidomide\/rituximab (R2) vs rituximab\/chemotherapy (R-Chemo) in previously untreated FL patients (ClinicalTrials.gov identifier: NCT01650701). The objective of the minimal residual disease (MRD) analysis was to determine the ability of a chemotherapy-free regimen to induce CMR. Of 440 French patients participating in the Lymphoma Study Association (LYSA) RELEVANCE MRD study, all 222 patients with a BIOMED-2\u2013detectable BCL2-JH translocation at diagnosis were analyzed. MRD was quantified by droplet digital polymerase chain reaction with a sensitivity \u226410\u22124. At week 24 (end of induction treatment), 98% and 78% of patients achieved CMR in peripheral blood (PB) and bone marrow (BM), respectively. Achievement of CMR (in PB and\/or BM) had a significant impact on progression-free survival (PFS), with 3-year PFS of 84% and 55% for patients with CMR and detectable MRD, respectively (P = .015). CMR at week 24 was reached more frequently in the R2 arm (105\/117; 90%) than in the R-Chemo arm (70\/90; 77%) (P = .022). The poor prognostic value in terms of PFS for the persistence of molecular disease was observed irrespective of treatment arm (interaction test, P = .31). In agreement with the clinical results of the RELEVANCE trial, our results show that R2 immunomodulatory treatment in first-line FL can achieve high rates of CMR.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001955","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:31:43Z","timestamp":1594949503000},"page":"3217-3223","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Lenalidomide\/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-2343","authenticated-orcid":false,"given":"Marie-Helene","family":"Delfau-Larue","sequence":"first","affiliation":[{"name":"Biological Hematology and Immunology Department, Groupe Hospitalier Mondor, INSERM U955, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Boulland","sequence":"additional","affiliation":[{"name":"Hematobiology Department, Centre Hospitalo-Universitaire (CHU) Pontchaillou, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-9687","authenticated-orcid":false,"given":"Asma","family":"Beldi-Ferchiou","sequence":"additional","affiliation":[{"name":"Biological Hematology and Immunology Department, Groupe Hospitalier Mondor, INSERM U955, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Regional Universitaire de Nancy, Vandoeuvre les Nancy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Maisonneuve","sequence":"additional","affiliation":[{"name":"Service d'Onco-H\u00e9matologie, Centre Hospitalier D\u00e9partemental Vend\u00e9e, La Roche-sur-Yon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8983","authenticated-orcid":false,"given":"Rene-Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, CHU Le Bocage, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-5419","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[{"name":"Unit\u00e9 H\u00e9mopathies Lympho\u00efdes, University Hospital Mondor, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Pica","sequence":"additional","affiliation":[{"name":"Service H\u00e9matologie, Centre Hospitalier (CH) M\u00e9tropole Savoie, Chamb\u00e9ry, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, CHU Pontchaillou, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"U1245 and D\u00e9partement d\u2019H\u00e9matologie, Centre Henri Becquerel, Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Eisenmann","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie, CH de Mulhouse, H\u00f4pital Emile Muller, Mulhouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-2128","authenticated-orcid":false,"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"Service d\u2019h\u00e9matologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, Nantes Excellence Trajectory Universit\u00e9 de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Hematology Department, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Godmer","sequence":"additional","affiliation":[{"name":"Service H\u00e9matologie, Centre Hospitalier Bretagne-Atlantique, Vannes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Glaisner","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Ren\u00e9 Huguenin, Saint-Cloud, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"Department of Hematology, CHU Montpellier, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"Departement de Bio-pathologie, Institut Paoli-Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles Andr\u00e9","family":"Salles","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6437-4189","authenticated-orcid":false,"given":"Thierry","family":"Fest","sequence":"additional","affiliation":[{"name":"Hematobiology Department, Centre Hospitalo-Universitaire (CHU) Pontchaillou, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie, Equipe d'Accueil 7365, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"issue":"20","key":"2020073010362002600_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9759","key":"2020073010362002600_B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"14","key":"2020073010362002600_B3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2020073010362002600_B4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2020073010362002600_B5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival\u2013A study from the groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020073010362002600_B6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11864-018-0594-1","article-title":"Minimal residual disease in indolent lymphomas: a critical assessment","volume":"19","author":"Grimaldi","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"2020073010362002600_B7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood.V98.4.940","article-title":"Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma","volume":"98","author":"Mandigers","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2020073010362002600_B8","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.2009.25.0852","article-title":"BCL-2\/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed\/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020073010362002600_B16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fonc.2019.00528","article-title":"The minimal residual disease in non-Hodgkin\u2019s lymphomas: from the laboratory to the clinical practice","volume":"9","author":"Galimberti","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"2020073010362002600_B9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2020073010362002600_B10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2008.07101.x","article-title":"Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients","volume":"141","author":"Hirt","year":"2008","journal-title":"Br J Haematol"},{"issue":"36","key":"2020073010362002600_B11","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1200\/JCO.2009.22.6258","article-title":"Quantitative PCR analysis for Bcl-2\/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma","volume":"27","author":"Goff","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020073010362002600_B12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2040620713480522","article-title":"Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma","volume":"4","author":"Lobetti-Bodoni","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"23","key":"2020073010362002600_B13","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2020073010362002600_B14","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2020073010362002600_B15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","article-title":"Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study","volume":"128","author":"Pott","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020073010362002600_B17","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"2020073010362002600_B18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2020073010362002600_B19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"2020073010362002600_B20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","article-title":"MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial","volume":"34","author":"Pott","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2020073010362002600_B21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020073010362002600_B22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"2020073010362002600_B23","first-page":"Abstract 1491","article-title":"Standardized IGH-based next-generation sequencing for MRD detection in follicular lymphoma [abstract]","volume":"130","author":"Pott","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/14\/3217\/1750503\/advancesadv2020001955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/14\/3217\/1750503\/advancesadv2020001955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T18:17:05Z","timestamp":1596133025000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/14\/3217\/461362\/Lenalidomiderituximab-induces-high-molecular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":23,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001955","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}